ProfileGDS5678 / 1421536_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 10% 9% 10% 10% 9% 9% 9% 9% 9% 10% 9% 9% 9% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.2582810
GSM967853U87-EV human glioblastoma xenograft - Control 22.232859
GSM967854U87-EV human glioblastoma xenograft - Control 32.2365510
GSM967855U87-EV human glioblastoma xenograft - Control 42.1990510
GSM967856U87-EV human glioblastoma xenograft - Control 52.189789
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.281529
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.241179
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.210019
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.201219
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.2291310
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.21629
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.206829
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.224579
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.22359